Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | ACHE | P22303 | 4/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9162336 | 0.88 | ALDH1A1 (0.83) | ALDH1A1SMN1; SMN2ACHEL3MBTL1KDM4E | |
| SCHEMBL11263177 | 0.84 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2ACHEOPRL1 | |
| SCHEMBL11259596 | 0.83 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2ACHEKDM4EHSD17B10 | |
| SCHEMBL2781893 | 0.83 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2ACHEL3MBTL1KDM4E | |
| SCHEMBL9363512 | 0.81 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL24994428 | 0.80 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2ACHEL3MBTL1KDM4E | |
| SCHEMBL1019672 | 0.80 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2ACHEL3MBTL1KDM4E | |
| SCHEMBL15797437 | 0.80 | ALDH1A1 (0.72) | ALDH1A1SMN1; SMN2ACHEL3MBTL1KDM4E | |
| SCHEMBL22854282 | 0.80 | ALDH1A1 (0.77) | ALDH1A1SMN1; SMN2ACHEL3MBTL1KDM4E | |
| SCHEMBL7296589 | 0.80 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2ACHEL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8350037-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA, S.A. (BE) | 2013-01-08 | — | — | US | disclosed |
| US-20100179124-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2010-07-15 | — | — | US | disclosed |
| US-4486431-A | Cardiotonic use of 4,5-dihydro-6-(4-pyridinyl)-3(2H)-pyridazinones | STERLING DRUG INC. (US) | 1984-12-04 | — | — | US | disclosed |
| US-4337253-A | 4,5-Dihydro-2-methyl-6-(4-pyridinyl)-3(2H)-pyridazinone and its use as a cardiotonic | STERLING DRUG INC. (US) | 1982-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179124-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | MAP3K6, MAPK1, MAP3K20 | ALDH1A1 2577/4885SMN1; SMN2 3067/4885ACHE 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.